Company Profile

Nexogen Inc
Profile last edited on: 2/14/2019      CAGE: 5F2T6      UEI: YULBN2FLVDL3

Business Identifier: DNA-based diagnostic products for rapid detection of respiratory, cardiovascular and infectious diseases
Year Founded
2009
First Award
2011
Latest Award
2019
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

7939 Silverton Avenue Suite 806
San Diego, CA 92126
   (858) 577-0422
   contact@nexogentech.com
   www.nexogentech.com
Location: Single
Congr. District: 52
County: San Diego

Public Profile

Nexogen, Inc. is developing DNA-based diagnostic products and portable instruments that enable integrated rapid detection of respiratory, cardiovascular and infectious diseases for food, veterinary and medical applications. The firm produces products that will allow fast and integrated sample processing, amplification and detection for the treatment and monitoring of respiratory, cardiovascular and infectious diseases. These products include molecular diagnostic products and platforms, which can be used in point of use, mobile and portable field applications.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2019 2 NIH $1,201,885
Project Title: A New Rapid DNA Platform for Neonatal Sepsis Diagnostics
2015 1 NIH $224,017
Project Title: Universal Modular Sample Preparation Device
2011 1 Army $69,478
Project Title: Differentiation of Leishmania in the Sand fly Vector

Key People / Management

  Dalibor Hodko -- Chief Executive Officer

  Elizabeth Mather -- Principal Investigator

Company News

There are no news available.